Spots Global Cancer Trial Database for sequencing
Every month we try and update this database with for sequencing cancer trials from around the world to help patients and their families find trials that might be right for them.
We offer this 100% free of charge and do not endorse any of the trials listed here, we hope it helps you or a loved one.
The following info and data is provided "as is" to help patients around the globe.
We do not endorse or review these studies in any way.
| Study title | NCT ID | Conditions | Interventions | Eligibility | Organization | Link |
|---|---|---|---|---|---|---|
| Correlation Between Specific Gene Mutationand Local Immune Microenvironment and Immunotherapy Efficacy in NSCLC | NCT04405661 | NSCLC | 18 Years - 70 Years | Guangzhou Institute of Respiratory Disease | ||
| PRecISion Medicine for Children With Cancer | NCT03336931 | Childhood Cance... Childhood Solid... Childhood Brain... Childhood Leuke... Refractory Canc... Relapsed Cancer | Molecular profi... | - 21 Years | Sydney Children's Hospitals Network | |
| Biomarkers of Response to Systemic Treatments in FH-deficient RCC | NCT05243173 | Metabolomics Renal Cell Carc... FH-Deficient RC... Systemic Treatm... | Sequencing | 18 Years - | RenJi Hospital | |
| Molecular Testing of Cancer by Integrated Genomic, Transcriptomic, and Proteomic Analysis | NCT02213822 | Solid Tumors Hematological M... | Molecular Analy... | 18 Years - | Rhode Island Hospital | |
| Molecular Analysis of 150 Lung Adenocarcinoma | NCT02843711 | Lung Adenocarci... | Sequencing | 18 Years - 99 Years | Hospices Civils de Lyon | |
| Molecular Testing of Cancer by Integrated Genomic, Transcriptomic, and Proteomic Analysis | NCT02213822 | Solid Tumors Hematological M... | Molecular Analy... | 18 Years - | Rhode Island Hospital | |
| Genetic Diversity of Toxoplasma Gondii in Cancer Patients | NCT04834076 | Toxoplasma Gond... Cancer | ELISA PCR Sequencing | 1 Year - | Sohag University | |
| Development of Diagnostics and Treatment of Urological Cancers | NCT02994758 | Prostate Carcin... Kidney Cancer Urothelial Carc... Testicular Canc... Penile Cancer | Personalised tr... | 18 Years - | Helsinki University Central Hospital | |
| cKIT, BRAF/NRAS Mutations in Advanced Melanoma : Clinical Outcome in Response to Tyrosine-kinase Inhibitors - KitMel Project | NCT01543113 | Melanoma | sequencing | - | Rennes University Hospital | |
| Patient Response to Immunotherapy Using Spliceosome Mutational Markers (PRISMM) | NCT04447651 | Metastatic Soli... SF3B1 Gene Muta... Spliceosome Mut... U2AF1 Gene Muta... SRSF2 Gene Muta... | Recommendation ... | 18 Years - | Sidney Kimmel Comprehensive Cancer Center at Johns Hopkins | |
| Evaluation of Gut Microbiome in Patients With Prostate Cancer | NCT03709485 | Prostate Cancer | rectal swab for... | 45 Years - | Ziv Hospital | |
| Survival Prolongation by Rationale Innovative Genomics | NCT03386929 | Non-small Cell ... Non-small Cell ... | Avelumab Axitinib Palbociclib | 18 Years - | Worldwide Innovative Network Association | |
| Feasibility Clinical Study of Targeted and Genome-Wide Sequencing | NCT01345513 | Solid Tumors | Sample Collecti... | 18 Years - | University Health Network, Toronto | |
| Analysis of Peripheral Nerve Sheath Tumors (PNSTs) in Neurofibromatosis Type 1 (NF1) Patients | NCT01218139 | Neurofibromatos... | - | KU Leuven | ||
| LCCC 1128: Open Label Phase II Trial of the BRAF Inhibitor (Dabrafenib) and the MEK Inhibitor (Trametinib) in Unresectable Stage III and Stage IV BRAF Mutant Melanoma; Correlation of Resistance With the Kinome and Functional Mutations | NCT01726738 | Stage III Melan... Stage IV Melano... Unresectable Me... BRAF Mutant Mel... | BRAF inhibitor ... | 18 Years - | UNC Lineberger Comprehensive Cancer Center | |
| Analysis of Peripheral Nerve Sheath Tumors (PNSTs) in Neurofibromatosis Type 1 (NF1) Patients | NCT01218139 | Neurofibromatos... | - | KU Leuven | ||
| Molecular Heterogeneity in Multilobar Low-grade Gliomas | NCT04000048 | Low-grade Diffu... | sequencing of t... | 18 Years - | University Hospital, Montpellier | |
| Sequencing Abiraterone and Enzalutamide in mCRPC | NCT02125357 | Metastatic Cast... | Abiraterone ace... Enzalutamide | 18 Years - | British Columbia Cancer Agency | |
| A Pilot Study Utilizing Proteomic and Genomic Profiling for Patients With Metastatic Breast Cancer | NCT01919749 | Metastatic Brea... | treated recomme... | 18 Years - | Translational Drug Development | |
| Optimal Sequencing of Treatment Options for Poor Risk mCRPC Previously Treated With Docetaxel | NCT03295565 | Prostate Cancer... Metastasis | Cabazitaxel Abiraterone Enzalutamide | 18 Years - | The Netherlands Cancer Institute | |
| Feasibility Study of Genomic Profiling Methods and Timing in Tumor Samples | NCT01703585 | Colorectal Canc... Breast Cancer Gynecological C... Metastatic Eligible for Ph... Melanoma Cancer | 18 Years - | University Health Network, Toronto | ||
| Dissecting the Pathways of Therapy Resistance in Early Breast Cancer | NCT04995575 | Breast Cancer | collection of t... | - | European Organisation for Research and Treatment of Cancer - EORTC | |
| Molecular Heterogeneity in Multilobar Low-grade Gliomas | NCT04000048 | Low-grade Diffu... | sequencing of t... | 18 Years - | University Hospital, Montpellier | |
| LCCC 1128: Open Label Phase II Trial of the BRAF Inhibitor (Dabrafenib) and the MEK Inhibitor (Trametinib) in Unresectable Stage III and Stage IV BRAF Mutant Melanoma; Correlation of Resistance With the Kinome and Functional Mutations | NCT01726738 | Stage III Melan... Stage IV Melano... Unresectable Me... BRAF Mutant Mel... | BRAF inhibitor ... | 18 Years - | UNC Lineberger Comprehensive Cancer Center | |
| Development of Diagnostics and Treatment of Urological Cancers | NCT02994758 | Prostate Carcin... Kidney Cancer Urothelial Carc... Testicular Canc... Penile Cancer | Personalised tr... | 18 Years - | Helsinki University Central Hospital | |
| Dissecting the Pathways of Therapy Resistance in Early Breast Cancer | NCT04995575 | Breast Cancer | collection of t... | - | European Organisation for Research and Treatment of Cancer - EORTC | |
| LCCC 1128: Open Label Phase II Trial of the BRAF Inhibitor (Dabrafenib) and the MEK Inhibitor (Trametinib) in Unresectable Stage III and Stage IV BRAF Mutant Melanoma; Correlation of Resistance With the Kinome and Functional Mutations | NCT01726738 | Stage III Melan... Stage IV Melano... Unresectable Me... BRAF Mutant Mel... | BRAF inhibitor ... | 18 Years - | UNC Lineberger Comprehensive Cancer Center | |
| Molecular Analysis of 150 Lung Adenocarcinoma | NCT02843711 | Lung Adenocarci... | Sequencing | 18 Years - 99 Years | Hospices Civils de Lyon | |
| Feasibility Clinical Study of Targeted and Genome-Wide Sequencing | NCT01345513 | Solid Tumors | Sample Collecti... | 18 Years - | University Health Network, Toronto | |
| Survival Prolongation by Rationale Innovative Genomics | NCT03386929 | Non-small Cell ... Non-small Cell ... | Avelumab Axitinib Palbociclib | 18 Years - | Worldwide Innovative Network Association | |
| A Pilot Study Utilizing Proteomic and Genomic Profiling for Patients With Metastatic Breast Cancer | NCT01919749 | Metastatic Brea... | treated recomme... | 18 Years - | Translational Drug Development | |
| Genome Sequencing of Human Cancer Tissues | NCT02105545 | Cancer | Cancer Treatmen... | - | New Mexico Cancer Care Alliance | |
| Molecular Testing of Cancer by Integrated Genomic, Transcriptomic, and Proteomic Analysis | NCT02213822 | Solid Tumors Hematological M... | Molecular Analy... | 18 Years - | Rhode Island Hospital | |
| Survival Prolongation by Rationale Innovative Genomics | NCT03386929 | Non-small Cell ... Non-small Cell ... | Avelumab Axitinib Palbociclib | 18 Years - | Worldwide Innovative Network Association |
Take Control of Your Skin and Body Changes Today.
Try out Spots for free, set up only takes 2 mins.
Join others from around the world:
